Thereafter, the autoregulatory amplification process allows the production from preMPF of large amounts of MPF ("amplified MPF"); this amplification depends on MPF itself.
The gap between the classical MPF and the current MPF thus reflects differences in the assay systems employed and quantification of cyclin B-Cdk1 activity.
MPF degradation further weakens the MPF activation loop promoting MPF inhibitory phosphorylation.
First, some kind of "initiator"—a signal independent of MPF allows the production of a small amount of MPF (i.e., "primary MPF") from preMPF.
There was an inverse correlation between the mean MPF and the variance in MPF over the 10-year study period (rs = −0.61, p<0.0001, Figure 3A).
During the microinjection assays described above, the MPF introduced into recipient oocytes functions as the primary MPF; it starts the MPF amplification loop in recipient oocytes despite the absence of the initiator.
This kinase phosphorylates a key residue on CDK-1, the CDK component of maturation promoting factor (MPF), which is required to make a functional, active MPF.
CyclinB, defined as one significant element of MPF, has been detected in our test to represent the activity of MPF.
To summarize the major findings of this study (Figure 6), demecolcine activates MPF by disassembling spindle microtubules and activating MAD2 while MG132 and caffeine activate MPF directly.
Wrinkles and dimples are the major forming defects in the MPF process, but numerical simulation is a feasible way to predict forming defects in MPF.
A workpiece can be formed section by section though the sectional MPF, and this technique makes it possible to manufacture large size parts in a small MPF press.
